Roivant Sciences Ltd. (ROIV) ist ein börsennotiertes Unternehmen im Gesundheitswesen Sektor, tätig in der Biotechnologie Branche. Der Hauptsitz des Unternehmens ist in London, United Kingdom. Der aktuelle CEO ist Matthew Gline.
ROIV hat IPO-Datum 2020-12-08, 908 Vollzeitbeschäftigte, gelistet an der NASDAQ Global Market, eine Marktkapitalisierung von $20.84B.
Roivant Sciences Ltd. is a biopharmaceutical and healthcare technology company headquartered in London that researches and develops innovative medicines across multiple therapeutic areas. The company's pipeline includes product candidates targeting oncologic malignancies, rare genetic disorders such as sickle cell disease and hypophosphatasia, and various inflammatory and dermatological conditions including psoriasis, atopic dermatitis, and vitiligo. Additional focus areas encompass autoimmune diseases, ophthalmologic disorders, and infectious diseases. Founded in 2014, Roivant combines drug development expertise with healthcare technology capabilities to address significant unmet medical needs globally.
